Patients who continued to receive pembrolizumab-based therapy after disease progression had longer overall survival than patients who stopped receiving pembrolizumab-based therapy.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Study participants were randomly assigned 1:1 to receive either sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, plus pembrolizumab, a PD-1-blocking antibody, or chemotherapy ...

Enriqueta Felip, MD, PhD, discusses the 3475A-D77 trial of subcutaneous pembrolizumab vs intravenous pembrolizumab plus chemotherapy in metastatic NSCLC.

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Gilead Sciences has reported positive topline data from the randomised Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy ...

Enriqueta Felip, MD, PhD, discusses the design of the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab in ...

Bicycle Therapeutics targets innovative cancer treatments with potential, like zelenectide pevedotin. Read here for an ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

Discover comprehensive insights into approved therapeutics and research developments targeting Prostate-Specific Membrane Antigen (PSMA). This product provides detailed competitor analysis, R&D stages ...

Reducing the infusion time for nivolumab and pembrolizumab to 10 minutes is feasible and safe, according to researchers.

Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...